THE NKF-KDOQI (2002) CKD DEFINITION AND CLASSIFICATION SYSTEM: Limitations and Problems Richard J. Glassock, MD, MACP David Geffen School of Medicine at.

Slides:



Advertisements
Similar presentations
The National Kidney Foundations Kidney Early Evaluation Program TM The National Kidney Foundations Kidney Early Evaluation Program TM Essex-Passaic Wellness.
Advertisements

Mayrene Hernandez, DO Advanced ProMed Inc. Billing and Management Solutions Board Certified in Family Medicine Clinical Assistant Professor for NSU.
Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
Chronic Kidney Disease/Dialysis Belinda Jim, MD January 15, 2009.
Chronic kidney disease: [insert title here] Insert name, title, date here Insert acknowledgements here.
The PREVEND Study: Screening for micro-albuminuria
CKD 1-5d GFR Stages Complications Referral Access/ESRD  Thomas Schumacher.
SLOW- COOKING THE BEANS “OR, HOW TO STOP WORRYING AND APPLY SOME LOVE TO THE KIDNEYS” AN APPROACH TO CKD SARA KATE LEVIN, MD JANUARY 2014.
General Practice Workshop This workshop was conceived and developed by Kidney Health Australia’s Kidney Check Australia Taskforce with particular thanks.
CKD In Primary Care Dr Mohammed Javid.
Chapter 1: CKD in the General Population 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
1 Prediabetes Comorbidities and Complications. 2 Common Comorbidities of Prediabetes Obesity CVD Dyslipidemia Hypertension Renal failure Cancer Sleep.
Welch Center Uniting Medicine & Public Health Prevalence of Albuminuria, and its Relationship to Decreased GFR and Outcomes Josef Coresh, MD, PhD Director,
Managing Chronic Kidney Disease in the Elderly Veteran Ann M. O’Hare, MA MD Staff Physician, VAPSHCS Assistant Professor of Medicine University of Washington.
Lesley Stevens MD Tufts-New England Medical Center
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
Use of clinical laboratory databases to enable early identification of patients at highest risk of developing end- stage kidney disease Dr David Kennedy.
Early Detection and Prevention of Renal Failure Linda Fried, MD, MPH.
Estimated GFR Based on Creatinine and Cystatin C
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub-intern under Nephrology Division, Department of Medicine in King Saud University.
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Section 4: Managing progression of CKD. Glomerulosclerosis Reduction in number of functioning glomeruli Increased blood flow to remaining nephrons Intraglomerular.
CKD: the primary/secondary care interface Daniel Ford Consultant Renal Physician UHCW.
Early detection of CKD CKD: Its out there somewhere.
RENAL DISEASE IN DIABETES
Health Care Costs Associated with Chronic Kidney Disease in Patients with Type II Diabetes Zita Shiue, MD Internal Medicine, R3 Chief of Medicine Conference.
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
Cystatin C– and Creatinine-Based Estimated Glomerular Filtration Rate, Vascular Disease, and Mortality in Persons With Diabetes in the U.S. Featured Article:
SM Gatmiri, MD, Nephrologist Imam Khomeini Hospital,
The National Kidney Foundation’s Kidney Early Evaluation Program TM “The Greater New York Experience” Ellen H. Yoshiuchi, MPS Division Program Director.
Section 6: Management in primary care Particular emphasis on nurse practitioner’s role.
If I had Chronic Kidney Disease: What would I want my Doctor to Know….. Liam Plant Department of Renal Medicine, Cork University Hospital Department of.
SHEFFIELD GUIDELINES: RENAL DISEASE IN DIABETES Dr Jenny Stephenson GP, Stannington Medical Centre
The management of renal problems in primary care Hugh Gallagher Consultant Nephrologist St Helier Hospital.
Section 3: CKD, CVD and mortality. Cardiovascular diseases in CKD patients Damage to the heart (Uraemic cardiomyopathy ) Damage to the arteries (Uraemic.
Section 2: Detection of CKD. What Tests Are Available? Direct GFR measurement –Inulin clearance –Radionuclides –Iohexol clearance 3 hr CrCl with Cimetidine.
La gestione del paziente diabetico: bisogni, percorsi e strumenti Metodi per lo studio della nefropatia Giuseppe Penno Dipartimento di Medicina Clinica.
Interobserver Reliability of Acute Kidney Injury Network (AKIN) criteria A single center cohort study Figure 2 The acute kidney injury network (AKIN) criteria.
Chapter 1: CKD in the General Population 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
1 به نام خدا. Epidemiology of chronic kidney disease 2.
Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.
Professor Tazeen H Jafar Duke-National University of Singapore & Aga Khan University, Karachi, Pakistan Chronic Kidney Disease- Integration into the NCD.
Sheffield Kidney Institute Global Kidney Academy CKD Micro-Lecture Epidemiology, Screening and Guidelines Professor Meguid El Nahas, PhD, FRCP Sheffield.
Am J Kidney Dis. 2014;63(6): R3 박세정 /prof. 이태원 Comparative Effectiveness of Early Versus Conventional Timing of Dialysis Initiation in Advanced.
Prevalence of Chronic Kidney Disease in an Urban Population
Original article Chronic Renal Failure A Neglected Comorbidity of COPD Raffaele Antonelli Incalzi, MD; Andrea Corsonello, MD; Claudio Pedone, MD; Salvatore.
بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ صدق الله العظيم.
내과 R1 문정락 / prof. 정경환 N Engl J Med 369;10 nejm.org 932 september 5, 2013.
Chronic Kidney Disease (CKD) Dr. Sham Sunder. Now we know why the titanic sank !! < 0.5 % 5- 10%
Section 1: CKD Epidemiology
National service framework for Renal
Section 2: Detection of CKD
Figure 1.1 Prevalence of CKD by stage among NHANES participants,
Nephrology Journal Club The SPRINT Trial Parker Gregg
Section 4: Managing progression of CKD
Section 6: Management in primary care
The LIVES Sub-analysis
Chapter 1: CKD in the General Population
Volume 80, Issue 1, Pages (July 2011)
Estimated GFR in Diabetes
Renal Pharmacy Group Beginners Lectures 2018
Volume 80, Issue 1, Pages (July 2011)
Chapter 1: Definition and classification of CKD
Chapter 1: CKD in the General Population
به نام خدا.
Meeting the challenges of the new K/DOQI guidelines
American Journal of Kidney Diseases
Evidence and Outcomes in CKD
Presentation transcript:

THE NKF-KDOQI (2002) CKD DEFINITION AND CLASSIFICATION SYSTEM: Limitations and Problems Richard J. Glassock, MD, MACP David Geffen School of Medicine at UCLA KDIGO Controversies Conference London, UK October 4, 2009

A Contrarians Lament

“A critic is a man who leaves no turn unstoned” George Bernard Shaw New York Times November 5, 1950

KDOQI-CKD (2002): Original Intent  Define chronic kidney disease (CKD) and to classify its stages, irrespective of underlying disease  Evaluate laboratory measurements for the assessment of kidney disease  Associate the level of kidney function with complications of CKD  Stratify the risk of loss of kidney function (ESRD) and development of cardiovascular disease (CVD) and other complications of CKD

Original Intent: Classification system was to be applied (unmodified) to both population analysis and to individual patient management

Chronic Kidney Disease (CKD): Classification- (NKF-K/DOQI-2002) Stage Kidney eGFR* Damage (ml/min/1.73m 2 ) 1 + ≥ NA NA NA < 15 (or dialysis) (*calculated from serum creatinine level by the abbreviated MDRD equation; NA= not applicable: findings must persist for ≥3 months)

The KDOQI-CKD Classification System Benefits (Real and Perceived)  Brought order to the chaos of nosology of CKD  Increased awareness of the “public health” problem of CKD in the general population and in general physicians  Galvanized research (clinical, basic, epidemiological) on the issue of CKD  Stimulated interest in early detection (population and targeted screening) of CKD  Minimized untimely start of dialysis

Chronic Kidney Disease: Citations in PubMed:

The KDOQI-CKD Classification System Limitations and Problems (Real and Perceived)  Described as a staging system, it is really a grading system based on arbitrary bands of eGFR values  Asserts that normal GFR is >90ml/min/1.73m2 and an GFR <60ml/min/1.73m2 is pathological across all adult ages, genders and ancestral groups  Ignores age- and gender-related changes in GFR  Linked to an imprecise measurement of GFR- the 4 variable eGFR (MDRD)  Allows the “diagnosis” of CKD based on eGFR alone  Conflates isolated “microalbuminuria” (in absence fo diabetes or corroborating evidence of “kidney damage”) with “kidney disease”  Links “complications” of “CKD” (e.g.CVD)to levels of eGFR, without reference to albuminuria

KDOQI-CKD (2002) Classification- Consequences of its Pitfalls  Overestimated the global societal burden of CKD (Stages 1-4)  Generated many unnecessary referrals from FP/GP to Nephrology (false- positive diagnosis of CKD)- leading to anxiety/expense  Promoted screening for CKD (de facto and overt) using eGFR  Promoted eGFR-defined CKD as a surrogate for CVD and ESRD risk– without consideration of role of albuminuria

CKD Prevalence-USA: NHANES (KDOQI-Based: ) (Coresh et al JAMA, 2007) Stage Prevalence Prevalence (%) (x 10 6 ) Total (One in every 7.6 persons over age % with Stage 3 CKD )

CKD-NHANES Prevalence of CKD (KDOQI) Stage 3 by Age ( )

CKD Prevalence Trends: eGFR (creatinine) v eGFR (cystatin C) ( vs NHANES; Foley R, et al CJASN 4:965, 2009)

Aging and GFR

Glomerular Filtration Rate (Cin) and Filtration Fraction (Cin/RPF) in Ageing (Davies and Shock, J Clin Invest 29:496, 1950)

CKD: eGFR in “Healthy” Caucasians by Gender (Wetzels,J et al;Nijmegen Biomedical Study, 2008) Males Females 95 th Percentile 50 th Percentile 5 th Percentile

CKD Prevalence: Kaiser-Permanente Age/Microalbuminuria-Adjusted and Standard KDOQI Criteria (Rutkowski, et al AJKD, 2009; Coresh, et al JAMA, 2008)

eGFR (MDRD): Precision and Bias

eGFR (MDRD) vs mGFR (Cin) (Botev, et al, CJASN, 2009)

Precision and Bias: eGFR (MDRD) vs mGFR (Cin) (Botev R, et al CJASN 4: , 2009)

Concordance of CKD Stage According to mGFR (C edta ) and eGFR (MDRD ) (Froissart, et al. JASN, 2005) (2095 subjects; 1995 with CKD/162 normal donors) mGFRStage 1 Stage 2 Stage 3 Stage 4 Stage 5 >9067%32%0.6% %64%21%0.2% %12%78%10% %79%4.2% < %32%65%

eGFR and Diagnosis of CKD: An Illustration  A 25 year old man with an eGFR of 55 ml/min/1.73m2 is 45% below the median for his age and -25 ml/min/1.73m2 below the 5th percentile for age and gender  A 75 year old man with an eGFR of 55ml/min/1.73m2 is 30% below the median for his age and +5 ml/min/1.73m2 above the 5th percentile for age and gender  WHICH ONE HAS SIGNIFiCANT CKD?

CKD and Complications: Cardiovascular Disease (CVD)

CKD-CVD: Adjusted HR for All-Cause Mortality and CV Events (Go et al, NEJM)

eGFR and Mortality Risk in the Elderly: Over 70 years of age (PROSPER; n=5804) (Ford I, et al PLoS Med 6:76, 2009)

All-Cause Mortality and eGFR Taiwan Health Management Institution Study (462,293 Adults-No abnormal proteinuria) (Wen, CP et al. The Lancet 371:2173, 2008)

All-Cause Mortality and Proteinuria (At same eGFR strata) Taiwan Health Management Institution Study; Lancet 2008

CKD Stage 3 Risk of Cardiovascular Disease (Brantsma AH, et al and PREVEND. NDT, 2008) (n= with CKD)

CVD events and CKD: PREVEND Study (van der Velde M, et al. ASN, 2008)

CKD and Complications: Progression to ESRD

The HUNT-II Study- Adjusted 10 year risk of ESRD according to eGFR and Albuminuria (Hallan S, et al JASN 20: , 2009)

The Problems with CKD Classification: Conclusions  eGFR (1999) and KDOQI-CKD (2002) interacts to greatly overestimate the societal burden of CKD- Stages 1-4  The “Diagnosis” of CKD by arbitrary eGFR thresholds (not adjusted for age and gender) leads to a significant error rate (false positive Stage 3 CKD)  Risk of Complications of CKD, based on eGFR alone are overemphasized- neglects the multiplier effect of albuminuria  Conflation of isolated “microalbuminuria” (without abnormal eGFR or diabetes) as a “kidney disease” lacks a firm rationale  Screening for CKD based on eGFR alone cannot be justified as cost-effective for prevention of ESRD or CVD

What is “CKD”?  Is it a Diagnosis?--- For a population or an individual?  Is it a Post-diagnostic step to grade the severity and determine the risks of progression or complications ?  Is it a non-specific means of categorizing patients with generic manifestations of specific kidney diseases?  Or all three?

“ It ought to be remembered that there is nothing more difficult to take in hand, more perilous to conduct or more uncertain in its success than to take the lead in the introduction of a new order of things” Niccolo Machiavelli- The Prince, 1513

THANK YOU !!!